Table 3.
Change in kidney function and biomarkers among participants in the follow-up study (n=198)
| Variables | Patients before Follow-Up | Patients after Follow-Up | P Value |
|---|---|---|---|
| CRP, mg/L | 56.2 (26.9–105.5) | 3.9 (1.3–17.8) | <0.001a |
| Serum albumin, g/L | 34.4±5.0 | 33.4±5.3 | 0.10b |
| BUN, mmol/L | 4.7 (3.5–5.9) | 4.6 (3.8–6.6) | 0.07a |
| SCR, μmol/L | 74.0 (61.0–89.0) | 72.5 (60.0–85.0) | 0.29a |
| Lymphocytes, 109/L | 0.80 (0.59–1.12) | 1.36 (0.87–1.82) | <0.001a |
| Eosinophils, 109/L | 0.00 (0.00–0.06) | 0.00 (0.07–0.29) | <0.001a |
| Serum IL-10, pg/ml | 6.7 (5.0–13.1) | 5.0 (5.0–5.2) | 0.01a |
| Serum IL-6, pg/ml | 24.3 (12.6–57.6) | 4.8 (2.0–22.4) | 0.008a |
| Serum IL-2R, U/ml | 794 (552–1065) | 505 (277–720) | <0.001a |
| Proteinuria | <0.001a | ||
| None | 21/198 (10.6%) | 132/198 (66.7%) | |
| ±/+ | 146/198 (73.8%) | 40/198(20.2%) | |
| ++/+++ | 31/198 (15.6%) | 4/198 (2.0%) | |
| Hematuria | <0.001a | ||
| None | 89/198 (44.9%) | 133/198 (67.2%) | |
| ±/+ | 84/198 (42.4%) | 33/198 (16.7%) | |
| ++/+++ | 25/198 (12.6%) | 10/198 (5.1%) | |
| AKI | <0.001a | ||
| No | 163/198 (82.3%) | 179/198 (90.4%) | |
| AKI stage 1 | 16/198 (8.1%) | 6/198 (3.0%) | |
| AKI stage 2 | 8/198 (4.0%) | 4/198 (2.0%) | |
| AKI stage 3 | 11/198 (5.6%) | 9/198 (4.5%) | |
| Resolution on lung involvement | 118/198 (59.6%) | ||
| Death | 29/198 (14.6%) | ||
| Death in critically ill group | 29/56 (51.8%) |
Data are presented as mean±SD or median (25th–75th percentiles) or as number and percentage. SCR, serum creatinine; ±/+, ± approximately 1+; ++/+++, 2+ approximately 3+.
a
Wilcoxon signed-rank test.
b
Paired t test.